Phase I study of iproplatin in pediatric patients

A Pediatric Oncology study group

C. B. Pratt, B. A. Kamen, N. Winick, P. Sartain, J. E. Champion, A. H. Ragab, M. P. Goren

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Iproplatin was evaluated in a phase I study in children to determine the maximum tolerated dosage. The dose limiting toxic effect was found to be myelosuppression, which in part was related to the amount of prior therapy with irradiation and other anticancer agents. The dosage recommended for phase II trials in children is 324 mg/m2 iv over 2 hours every 3-4 weeks.

Original languageEnglish (US)
Pages (from-to)87-88
Number of pages2
JournalCancer Treatment Reports
Volume71
Issue number1
StatePublished - 1987

Fingerprint

Pediatrics
Poisons
Antineoplastic Agents
iproplatin
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pratt, C. B., Kamen, B. A., Winick, N., Sartain, P., Champion, J. E., Ragab, A. H., & Goren, M. P. (1987). Phase I study of iproplatin in pediatric patients: A Pediatric Oncology study group. Cancer Treatment Reports, 71(1), 87-88.

Phase I study of iproplatin in pediatric patients : A Pediatric Oncology study group. / Pratt, C. B.; Kamen, B. A.; Winick, N.; Sartain, P.; Champion, J. E.; Ragab, A. H.; Goren, M. P.

In: Cancer Treatment Reports, Vol. 71, No. 1, 1987, p. 87-88.

Research output: Contribution to journalArticle

Pratt, CB, Kamen, BA, Winick, N, Sartain, P, Champion, JE, Ragab, AH & Goren, MP 1987, 'Phase I study of iproplatin in pediatric patients: A Pediatric Oncology study group', Cancer Treatment Reports, vol. 71, no. 1, pp. 87-88.
Pratt CB, Kamen BA, Winick N, Sartain P, Champion JE, Ragab AH et al. Phase I study of iproplatin in pediatric patients: A Pediatric Oncology study group. Cancer Treatment Reports. 1987;71(1):87-88.
Pratt, C. B. ; Kamen, B. A. ; Winick, N. ; Sartain, P. ; Champion, J. E. ; Ragab, A. H. ; Goren, M. P. / Phase I study of iproplatin in pediatric patients : A Pediatric Oncology study group. In: Cancer Treatment Reports. 1987 ; Vol. 71, No. 1. pp. 87-88.
@article{cf1db27a23e34f558021b3ea37e823b7,
title = "Phase I study of iproplatin in pediatric patients: A Pediatric Oncology study group",
abstract = "Iproplatin was evaluated in a phase I study in children to determine the maximum tolerated dosage. The dose limiting toxic effect was found to be myelosuppression, which in part was related to the amount of prior therapy with irradiation and other anticancer agents. The dosage recommended for phase II trials in children is 324 mg/m2 iv over 2 hours every 3-4 weeks.",
author = "Pratt, {C. B.} and Kamen, {B. A.} and N. Winick and P. Sartain and Champion, {J. E.} and Ragab, {A. H.} and Goren, {M. P.}",
year = "1987",
language = "English (US)",
volume = "71",
pages = "87--88",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Phase I study of iproplatin in pediatric patients

T2 - A Pediatric Oncology study group

AU - Pratt, C. B.

AU - Kamen, B. A.

AU - Winick, N.

AU - Sartain, P.

AU - Champion, J. E.

AU - Ragab, A. H.

AU - Goren, M. P.

PY - 1987

Y1 - 1987

N2 - Iproplatin was evaluated in a phase I study in children to determine the maximum tolerated dosage. The dose limiting toxic effect was found to be myelosuppression, which in part was related to the amount of prior therapy with irradiation and other anticancer agents. The dosage recommended for phase II trials in children is 324 mg/m2 iv over 2 hours every 3-4 weeks.

AB - Iproplatin was evaluated in a phase I study in children to determine the maximum tolerated dosage. The dose limiting toxic effect was found to be myelosuppression, which in part was related to the amount of prior therapy with irradiation and other anticancer agents. The dosage recommended for phase II trials in children is 324 mg/m2 iv over 2 hours every 3-4 weeks.

UR - http://www.scopus.com/inward/record.url?scp=0023130855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023130855&partnerID=8YFLogxK

M3 - Article

VL - 71

SP - 87

EP - 88

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 1

ER -